Financial News

Crown Laboratories To Acquire Revance Therapeutics in $924 Million Merger Deal

Revance’s aesthetics portfolio includes Daxxify, a Botox competitor.

Author Image

By: Christine Esposito

Editor-in-Chief

Crown Laboratories, Inc. and Revance Therapeutics, Inc. have entered into a merger agreement in a deal valued at $924 million. Revance, based in Nashville, TN, is a biotech company focused on aesthetic and therapeutic offerings. The Nasdaq-traded company’s portfolio includes Daxxify (DaxibotulinumtoxinA-lanm), an FDA -pproved injectable peptide formulated neuromodulator that competes with Botox, and the RHA Collection, an FDA approved hyaluronic acid filler line. Crown will acquire a...

Continue reading this story and get 24/7 access to Happi for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Happi Newsletters